Future studies to determine the efficacy of combined targeting of these factors (or re-expression in the case of p53) along with FZD7 inhibition will yield important pre-clinical information, which is likely the future of cancer therapy given the failure of mono-therapies to provide a robust clinical outcome. The gene discussed is TP53; the disease is cancer.